These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 35277559)
1. CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas. Ma K; Chen X; Liu W; Chen S; Yang C; Yang J Sci Rep; 2022 Mar; 12(1):4295. PubMed ID: 35277559 [TBL] [Abstract][Full Text] [Related]
2. S100A10 Is a New Prognostic Biomarker Related to the Malignant Molecular Features and Immunosuppression Process of Adult Gliomas. Ma K; Chen S; Chen X; Yang C; Yang J World Neurosurg; 2022 Sep; 165():e650-e663. PubMed ID: 35779750 [TBL] [Abstract][Full Text] [Related]
3. CD93 is Associated with Glioma-related Malignant Processes and Immunosuppressive Cell Infiltration as an Inspiring Biomarker of Survivance. Ma K; Chen S; Chen X; Zhao X; Yang J J Mol Neurosci; 2022 Oct; 72(10):2106-2124. PubMed ID: 36006582 [TBL] [Abstract][Full Text] [Related]
4. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages. Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967 [No Abstract] [Full Text] [Related]
5. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866 [TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas. Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444 [TBL] [Abstract][Full Text] [Related]
7. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas. Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J Front Oncol; 2021; 11():611038. PubMed ID: 33937022 [TBL] [Abstract][Full Text] [Related]
8. Transcriptome profile and clinical characterization of ICOS expression in gliomas. Wang J; Shi F; Shan A Front Oncol; 2022; 12():946967. PubMed ID: 36276141 [TBL] [Abstract][Full Text] [Related]
9. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients. Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941 [TBL] [Abstract][Full Text] [Related]
10. DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas. Chang X; Pan J; Zhao R; Yan T; Wang X; Guo C; Yang Y; Wang G Front Immunol; 2022; 13():917014. PubMed ID: 35812432 [TBL] [Abstract][Full Text] [Related]
11. PLVAP is associated with glioma-associated malignant processes and immunosuppressive cell infiltration as a promising marker for prognosis. Ma K; Chen X; Zhao X; Chen S; Yang J Heliyon; 2022 Aug; 8(8):e10298. PubMed ID: 36033326 [TBL] [Abstract][Full Text] [Related]
12. Large-scale analysis reveals the specific clinical and immune features of CD155 in glioma. Liu F; Huang J; Xiong Y; Li S; Liu Z Aging (Albany NY); 2019 Aug; 11(15):5463-5482. PubMed ID: 31377744 [TBL] [Abstract][Full Text] [Related]
13. The RPL4P4 Pseudogene Is a Prognostic Biomarker and Is Associated with Immune Infiltration in Glioma. Wang Z; Aili Y; Wang Y; Maimaitiming N; Qin H; Ji W; Fan G; Li B Oxid Med Cell Longev; 2022; 2022():7967722. PubMed ID: 35993018 [TBL] [Abstract][Full Text] [Related]
14. Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma. Wang X; Yang Q; Liu N; Bian Q; Gao M; Hou X Pathol Oncol Res; 2021; 27():1609825. PubMed ID: 34629960 [No Abstract] [Full Text] [Related]
15. Correlation of immune phenotype with IDH mutation in diffuse glioma. Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337 [TBL] [Abstract][Full Text] [Related]
16. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617 [TBL] [Abstract][Full Text] [Related]
17. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma. Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612 [TBL] [Abstract][Full Text] [Related]
18. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas. Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008 [TBL] [Abstract][Full Text] [Related]
19. Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients. Yan Z; Gao Y; Yu J; Shen Z; Bu X J Immunol Res; 2022; 2022():8972730. PubMed ID: 35647198 [TBL] [Abstract][Full Text] [Related]
20. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]